S-adenosyl-methionine in depression: A comprehensive review of the literature

Current Psychiatry Reports

Volumn 5, Issue 6, 2003, Pages 460-466

  Papakostas, George I ^a   Alpert, Jonathan E ^b   Fava, Maurizio ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ADENOSYLHOMOCYSTEINASE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; HOMOCYSTEINE; IMIPRAMINE; MAPROTILINE; MECOBALAMIN; MEMBRANE LIPID; METHIONINE SYNTHASE; MUSCARINIC RECEPTOR; NEUROTRANSMITTER RECEPTOR; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PLACEBO; PROLACTIN RECEPTOR; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ADENOSYL METHIONINE 1,4 BUTANEDISULFONATE; ADENOSYL-METHIONINE 1,4-BUTANEDISULFONATE; DRUG DERIVATIVE;

CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DEPRESSION; DISEASE EXACERBATION; DNA METHYLATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; INSOMNIA; MANIA; MEDICAL LITERATURE; MEMBRANE FLUIDITY; NERVE CELL MEMBRANE; NERVOUSNESS; PATHOPHYSIOLOGY; PHOSPHOLIPID METHYLATION; RETROSPECTIVE STUDY; REVIEW; BRAIN; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; MAJOR DEPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; S-ADENOSYLMETHIONINE; TREATMENT OUTCOME;

EID: 2942673042     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-003-0085-2     Document Type: Review

References (76)

1. Bottiglieri T, Hyland K: S-adenosylmethionine in psychiatric and neurological disorders: a review. Acta Neurol Scand 1994, 154:19-26.
2. Bottiglieri T: S-adenosyl-L-methionine (SAMe): from the bench to the bedside-molecular basis of a pleiotropic molecule. Am J Clin Nutr 2002, 75(suppl):1151S-1157S.
3. Baldessarini RJ: The neuropharmacology of S-adenosyl-L-methionine. Am J Med 1987, 83:95-103.
4. Cestaro B: Effects of arginine, s-adenosylmethionine and polyamines on nerve regeneration. Acta Neurol Scand 1994, 154:32-41.
5. Bottiglieri T, Laundry M, Crellin R, et al.: Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000, 69:228-232.
6. Bottiglieri T, Chary CK, Laundy M, et al.: Transmethylation in depression. Ala J Med Sci 1988, 25:296-301.
7. Bottiglieri T, Godfrey P, Flynn T, et al.: Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatr 1990, 53:1096-1098.
8. Tolbert LC, Monti JA, O'Shields H: Defects in transmethylation and membrane lipids in schizophrenia. Psychopharmacol Bull 1983, 19:594-599.
9. Smythies JR, Alarcon RD, Bancroft AJ: Role of the one-carbon cycle in neuropsychiatry. In Biological Methylation and Drug Design. Edited by Borchardt R, Creveling C, Ueland P. Clifton: Humana Press; 1986.
10. Arinami T, Yamada N, Yamakawa-Kobayashi K, et al.: Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Gen 1997, 74:526-528.
11. Hickie I, Scott E, Naismith S, et al.: Late-onset depression: genetic, vascular and clinical contributions. Psychol Med 2001, 31:1403-1412.
12. Bjelland I, Tell GS, Vollset SE, et al.: Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 2003, 60:618-626.
13. Hector M, Burton JR: What are the psychiatric manifestations of vitamin B12 deficiency? J Am Geriatr Soc 1988, 36:1105-1112.
14. Tiemeier H, Van Tuijl HR, Holman A, et al.: Vitamin B(12), folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002, 159:2099-2101.
15. Levitt AJ, Joffe RT: Folate, B12, and thyroid function in depression. Biol Psychiatry 1993, 33:52-53.
16. Bell IR, Edman JS, Morrow FD, et al.: B complex vitamin patterns in geriatric and young adult inpatients with major depression. JAGS 1991, 39:252-257.
17. Bottiglieri T, Hyland K, Laundry M, et al.: Folate deficiency, biopterin and monoamine metabolism in depression. Psychol Med 1992, 22:871-876.
18. Abou-Saleh MT, Coppen A: Serum and red blood cell folate in depression. Acta Psychiatr Scand 1989, 80:78-82.
19. Carney MW, Sheffield BF: Serum folic acid and B12 in 272 psychiatric in-patients. Psychol Med 1978, 8:139-144.
20. Carney MWP, Chary TKN, Laundy M, et al.: Red cell folate concentrations in psychiatric inpatients. J Affect Disord 1990, 19:207-213.
21. Lee S, Wing YK, Fong S: A controlled study of folate levels in Chinese inpatients with major depression in Hong Kong. J Affect Disord 1998, 49:73-77.
22. Ghadirian AM, Anath J, Engelsman F: Folic acid deficiency in depression. Psychosomatics 1980, 21:926-929.
23. Wilkinson Am, Anderson DN, Abou-Saleh MT, et al.: 5⋯thyltetrahydrofolate level in the serum of depressed subjects and its relationship to the outcome of ECT. J Affect Disord 1994, 32:163-168.
24. Fava M, Borus JS, Alpert JE, et al.: Folate, B12, and homocysteine in major depressive disorder. Am J Psychiatry 1997, 154:426-428.
25. Morris MS, Fava M, Jacques PF, et al.: Depression and folate status in the US population. Psychother Psychosom 2003, 72:80-87.
26. Wesson VA, Levitt AJ, Joffe RT: Change in folate status with antidepressant treatment. Psychiatry Res 1994, 53:313-322.
27. Bell IR, Edman J, Marby DW, et al.: Vitamin B12 and folate status in acute geropsychiatric inpatients: affective and cognitive characteristics of a vitamin non-deficient population. Biol Psychiatry 1990, 27:125-137.
28. Alpert M, Silva RR, Pouget ER: Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol 2003, 23:309-313.
29. Levitt AJ, Wesson VA, Joffe RT: Impact of suppression of thyroxine on folate status during acute antidepressant therapy. Psychiatry Res 1998, 79:123-129.
30. Coppen A, Bailey J: Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo controlled trial. J Affect Disord 2000, 60:121-130.
31. Reynolds EH, Preece JM, Bailey J, Coppen A: Folate deficiency in depressive illness. Br J Psychiatry 1970, 117:287-292.
32. Godfrey PSA, Toone BK, Carney MWP, et al.: Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990, 36:392-395.
33. Guarardi G, Fava M, Mazzi F, LaGreca P: An open trial of methyltetrahydrofolate (MTHF) in elderly depressed patients. Ann Clin Psychiatry 1993, 5:101-106.
34. Alpert JE, Mischoulon D, Rubenstein GE, et al.: Folinic acid as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry 2002, 14:33-38.
35. Coppen A, Chaudhry S, Swade C: Folic acid enhances lithium prophylaxis. J Affect Disord 1986, 10:9-13.
36. Agency for Healthcare Research Quality (AHRQ): S-sdenosyl-l-methionine for treatment of depression, osteoarthritis, and liver disease. http://www.ahrq.org/clinic/evrptfiles.htm#same.
37. Bressa GM: S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 1994, 154:7-14.
38. Pinzello A, Andreoli V: Le transmetilazioni SAM-dipendenti nelle sindromi depressive. Valutazione dell-effetto terapeutico della S-adenosilmetionina con la scala di Hamilton. Quad Ter Sper Suppl Bioch Biol Sper 1972, 2:3-11.
39. Fazio C, Andreoli V, Agnoli A, et al.: Effetti terapeutici e meccanismo d'azione della S-adenosil-l-metionina (SAMe) nelle sindromi depressive. Minerva Med 1973, 64:1515-1529.
40. Agnoli A, Fazio C, Andreoli V. Disturbi neuropsichiatrici e transmetilazioni. Effetti terapeutici della S adenosil-l-metionina. Clin Ter 1975, 75:567-579.
41. Mantero M, Pastorino P: Sindromi depressive, malattie cutanee e transmetilazioni. Effetti terapeutici della s-adenosyl-l-metionina. Gazz Med Ital 1976, 135:707-716.
42. Andreoli V, Campedelli A, Maffei F: La s-adenosil-l-metionina (SAMe) in geropsichiatria: uno studio clinico controllato "in aperto" nelle sindromi depressive dell'eta' senile. G Gerontol 1977, 25:172-180.
43. Barberi A, Pusateri C: Sugli effetti clinici della s-adenosil-l-metionina (SAMe) nelle sindromi depressive. Minerva Psichiatr 1978, 19:235-243.
44. Salvadorini F, Galeone F, Saba P, et al.: Evaluation of s-adenosylmethionine (SAMe) effectiveness on depression. Curr Ther Res 1980, 27:908-918.
45. Carney MW, Edeh J, Bottiglieri T, et al.: Affective illness and s-adenosylmethionine: a preliminary report. Clin Neuropharmacol 1986, 9:379-385.
46. Lipinski JF, Cohen BM, Frankenburg F, et al.: An open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry 1984, 141:448-450.
47. Fava M, Gianelli A, Rapisarda V, et al.: Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res 1995, 56:295-297.
48. Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H: Efficacy of s-adenosyl-l-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992, 44:257-262.
49. Bell KM, Plon L, Bunney WE Jr., Potkin SG: S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry 1988, 145:1110-1114.
50. Janicak PC, Lipinski J, Davis JM, et al.: S-adenosylmethionine in depression: a literature review and preliminary report. Ala J Med Sci 1988, 25:306-313.
51. Delle Chiaie R, Pancheri P, Scapicchio P: Efficacy and tolerability of oral and intramuscular S-adenosyl-l-methionine 1,4-butane-disulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr 2002, 76(suppl):1172S-1176S.
52. Pancheri P, Scapicchio P, Chiaie RD: A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol 2002, 5:287-294.
53. Caruso I, Fumagalli M, Boccassini L, et al.: Antidepressant activity of S-adenosyl-methionine. Lancet 1984, I:904.
54. Loehrer FM, Schwab R, Angst CP, et al.: Influence of oral S-adenosylmethionine on plasma 5-methyltetrahydrofolate, S-adenosylhomocysteine, homocysteine and methionine in healthy humans. J Pharmacol Exp Ther 1997, 282:845-850.
55. Iruela LM, Minguez L, Merino J, Monedero G: Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry 1993, 150:522.
56. Castagna A, Le Grazie C, Accordini A: Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection: effect of parenteral treatment with SAMe. Neurology 1995, 45:1678-1683.
57. Rosenbaum JF, Fava M, Falk WE, et al.: The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990, 81:432-436.
58. Fava M, Rosenbaum JF, MacLaughlin R, et al.: Neuroendocrine effects of s-adenosyl-l-methionine, a novel putative antidepressant. J Psychiatric Res 1990, 24:177-184.
59. Fava M, Rosenbaum JF, Birnbaum R, et al.: The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand 1992, 86:42-45.
60. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH: Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 1990, 147:591-595.
61. Salmaggi P, Bressa GM, Nicchia G, et al.: Double-blind, placebo-controlled study of s-adenosyl-l-methionine in depressed post-menopausal women. Psychother Psychosom 1993, 59:34-40.
62. Bell MB, Carreon D, Plon L, et al.: Oral s-adenosylmethionine in the treatment of depression: a double-blind comparison with desipramine. Study report. BioResearch File 1990.
63. De Vanna M, Rigamonti R: Oral S-adenosyl-L-methionine in depression. Curr Ther Res 1992, 52:478-485.
64. Greenberg RP, Bornstein RF, Greenberg MD, Fisher S: A meta-analysis of antidepressant outcome under "blinder" conditions. J Consult Clin Psychol 1992, 5:664-669.
65. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
66. Scott JM, Molloy AM, Kennedy DG, et al.: Effects of the disruption of transmethylation in the central nervous system: an animal model. Acta Neurol Scand 1994, 154(suppl):27-31.
67. Cohen BM, Satlin A, Zubenko GS: S-adenosyl-l-methionine in the treatment of Alzheimer's disease. J Clin Psychopharmacol 1988, 8:43-47.
68. Heron DS, Shinitzky M, Turnbull J, Shatill SJ: Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Procl Natl Acad Sci U S A 1980, 77:7463-7467.
69. Hirata F, Axelrod J: Phospholipid methylation and biological signal transmission. Science 1980, 209:1082-1090.
70. Crews FT: Effects of membrane fluidity on secretion and receptor stimulation. Psychopharmacol Bull 1982, 18:135-143.
71. Becher A, White J, McIlhinney R, Jeffrey RA: The [gamma]-aminobutyric acid receptor B, but not the metabotropic glutamate receptor type-1, associates with lipid rafts in the rat cerebellum. J Neurochem 2001, 79:787-795.
72. Ohvo-Rekika H, Ramtedt B, Leppimaki P, Slotte P: Cholesterol interactions with phospholipids in membranes. Prog Lipid Res 2002, 41:66-97.
73. Hirata F, Strittmatter WJ, Axelrod J: Beta-adrenergic receptor agonists increase phospholipid methylation, membrane fluidity, and beta-adrenergic receptor-adenylate cyclase coupling. Proc Natl Acad Sci U S A 1979, 76:368-372.
74. Muccioli G, Scordamaglia A, Bertacco S, Di Carlo R: Effect of S-adenosyl-l-methionine on brain muscarinic receptors of aged rats. Eur J Pharmacol 1992, 227:293-299.
75. Pavia J, Martos F, Gonzalez-Correa JA, et al.: Effect of S-adenosyl methionine on muscarinic receptors in young rats. Life Sci 1997, 60:825-832.
76. Muccioli G, Di Carlo R: Adenosyl-l-methionine restores prolactin receptors in the aged rabbit brain. Eur J Pharmacol 1989, 166:223-230.